UnicoCell Biomed (向榮生技) announced on the 21st that its stem-cell-derived exosome products have received Cosmetic Product Notification approval from the Philippines Food and Drug Administration. This marks a major step in the company’s expansion into the ASEAN market following its entry into Japan.

• ASEAN Compliance: The approval confirms that UnicoCell’s products meet the ASEAN Cosmetic Directive (ACD) standards, facilitating future launches in other Southeast Asian nations.
• Pharmaceutical Grade Quality: UnicoCell holds a Drug Master File (DMF) with the US FDA for its exosome raw materials. This ensures that while the product is sold for cosmetic use, it is manufactured under rigorous pharmaceutical-grade standards.
• Proprietary Edge: The company’s patented manufacturing process, which significantly increases exosome concentration and purity, won the Bronze Award at the 2024 National Drug Technology Research and Development Awards. UnicoCell is now leveraging local partners to penetrate the growing Philippine medical aesthetics market.

Resource: 向榮生技前進東南亞 外泌體取得菲律賓化妝品資格認證